Novartis | NVS - Le Bénéfice D'Exploitation

Prix De L'Action
149.79
Variation Quotidienne
-2.26 -1.49%
Mensuellement
-3.22%
Annuel
35.34%
Q2 Prévisions
150.72




Le Bénéfice D'Exploitation Changement Date
AbbVie USD 5.81B 1.23B 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bausch Health Companies USD 719M 2M 2025-12
Biogen USD 659.6M 192.2M 2025-09
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Canopy Growth CAD -12.66M 1.64M 2025-12
Corcept Therapeutics USD 4.49M 5.73M 2025-12
Drreddys Laboratories INR 14.33B 2.51B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
J&J USD 6.62B 1.03B 2026-03
Merck USD 6.24B 318M 2025-12
Novartis USD 4.06B 437M 2025-12
Novartis USD 4.06B 521M 2025-12
Pacira USD 3.19M 9.96M 2025-12
Perrigo USD 84.4M 9M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 82.49M 2.82M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
Sanofi EUR 1.5B 2.29B 2025-12
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
Zoetis USD 835M 101M 2025-12